e327 7
Nimodipine remains the only modality proven to reduce the incidence of infarction
Nimodipine is a dihydropyridine agent that blocks voltage-gated calcium channels and has a dilatory effect on arterial smooth muscle
The treatment of CV includes non-invasive measures, like oral nimodipine and induced hypertension, but also invasive measures
Confirmation of cerebral vasospasm and/or delayed cerebral ischemia by one of these diagnostic techniques should prompt clinicians to initiate treatment with
(2004) demonstrated in the early 2000s that intra-arterial nimodipine (IAN) is an effective treatment for symptomatic vasospasm showing an
The treatment of CV includes non-invasive measures, like oral nimodipine and induced hypertension, but also invasive measures
Treatment of Ruptured Cerebral Aneurysms
Nimodipine is a second generation calcium channel blocker used in the treatment of cerebral vasospasm after subarachnoid hemorrhage
Clinical deterioration such as focal neurological deficits or a decrease in
Nimodipine currently remains the only drug approved by the US Food and Drug Administration for cerebral vasospasm treatment [18–28]
Cerebral vasospasm following head trauma is characterized by an earlier onset than that of aneurysmal subarachnoid hemorrhage controlled, multicenter trial examined the effects of nimodipine treatment (versus placebo) on the incidence of vasospasm (radiographic and clinical) and six-month Glasgow outcome scores in tSAH
Background: Despite decades of research, cerebral vasospasm (CV) continues to account for high morbidity and mortality in patients who survive their initial aneurysmal subarachnoid hemorrhage
Liu et al
The study also remarkably found that a large amount of subarachnoid blood on computed tomography (CT) scan did not work against the effect
Severe refractory cerebral vasospasm (CV) is a major cause of disability and death in patients with aneurysmal subarachnoid hemorrhage (SAH)
Methods: Records of children with a confirmed diagnosis of subarachnoid hemorrhage who received nimodipine between January 1, 2005 and August 31, 2013
A tota
Cerebral vasospasm occurs in more than half of all patients and is recognized as the main cause of delayed cerebral ischemia after subarachnoid hemorrhage
Due to positive effects of per os nimodipine, intraarterial nimodipine application is used in patients with DCI
Milrinone for refractory cerebral vasospasm with delayed cerebral ischemia
Although this complication is at times reversible, it may develop into a cerebral infarction []
Efficacy of intra-arterial nimodipine in the treatment of cerebral vasospasm complicating subarachnoid haemorrhage